SYNTHETIC DEMONSTRATION — no real student or patient. Not a medical device.

allergy-asthma

Xolair for Chronic Hives: Cost and Insurance Coverage

Xolair (omalizumab) is FDA-approved for chronic spontaneous urticaria in people 12 and older who remain symptomatic despite antihistamines. List price is $1,000–$3,000 per injection (300 mg every four weeks). Most commercial plans cover it with prior authorization; manufacturer copay assistance can significantly reduce out-of-pocket costs.

Talk to a clinician

Gale can match you with a licensed clinician for a visit.

Find care →

What is Xolair and how was it approved for chronic hives?

Xolair (omalizumab) is a monoclonal antibody that works by binding to immunoglobulin E (IgE) in the blood, reducing circulating free IgE and causing IgE receptors on immune cells to down-regulate. Its exact mechanism in chronic spontaneous urticaria (CSU) is not fully understood, but its clinical benefit is well-documented 1.

The FDA approved Xolair for CSU in March 2014 for adults and adolescents 12 years and older who continue to have hives despite H1-antihistamine treatment. The approval was based in part on the ASTERIA II trial, a randomized, double-blind, placebo-controlled Phase III study that found the 300 mg dose produced significantly greater reductions in weekly itch-severity scores compared to placebo (mean change -9.8 vs. -5.1 at week 12, P<0.001) 2. Dosing for CSU is 150 or 300 mg subcutaneously every four weeks, not dependent on weight or IgE level.

What does Xolair cost without insurance?

The retail (list) price for a single Xolair injection session — the 300 mg dose (two 150 mg injections) used for most CSU patients — generally falls between $1,000 and $3,000, depending on the dose and the pharmacy or infusion center. Because most people with chronic hives receive 300 mg every four weeks, annual drug costs alone can reach $15,000–$40,000 at list price without any coverage.

These are list prices, not what most insured patients pay. Actual cash-pay prices vary considerably depending on whether you use an independent infusion center, a hospital outpatient clinic, or a specialty pharmacy.

Does insurance typically cover Xolair for hives?

Xolair's FDA approval for CSU makes it a covered benefit under most commercial insurance plans and Medicare Part B (when administered in-office) 1.

The catch is prior authorization (PA) — virtually every insurer requires it. A typical PA documentation request includes:

  • Diagnosis of chronic spontaneous urticaria lasting at least 6 weeks
  • Adequate trial of high-dose H1 antihistamines that did not adequately control symptoms
  • Why Xolair is medically necessary

Approvals often come through when criteria are clearly met, but the paperwork can take days to weeks. If the first PA is denied, your clinician can file an appeal or request a peer-to-peer review with the insurance medical director — many step-therapy denials are overturned at this stage.

What if my insurance denies it or I have a high copay?

Manufacturer copay assistance. Genentech (the maker of Xolair) offers a copay card program that can bring eligible commercially insured patients' out-of-pocket cost to $0 per injection, up to an annual maximum. Patients on government insurance (Medicare, Medicaid) are generally not eligible for copay cards but may qualify for patient assistance programs.

Patient assistance programs. The Genentech Access Solutions program provides free or reduced-cost Xolair to qualifying uninsured or underinsured patients who meet income thresholds. Your allergist's office can help you apply.

Appeal a denial. If a PA is denied based on step therapy, your clinician can write a letter of medical necessity and request a peer-to-peer call. Many step-therapy denials are overturned when the clinical criteria are clearly documented.

How are the injections given and how long does treatment continue?

For chronic spontaneous urticaria, the standard dosing is 300 mg (two 150 mg injections) subcutaneously every four weeks 1. The injection is given in a clinician's office or infusion center; you remain for approximately 30 minutes of observation afterward because there is a small risk of anaphylaxis that can occur with any dose, including doses given after more than a year of treatment 3.

Many patients see meaningful relief within the first few weeks; others take three to four months to respond. The appropriate duration of therapy for CSU has not been formally established — your allergist will re-evaluate periodically to weigh continued benefit against cost and inconvenience.

How to prepare for the cost conversation with your allergist

Before your appointment:

1. Call your insurer and ask whether Xolair is on your formulary for chronic urticaria and what the prior authorization requirements are. 2. Ask about your cost-sharing — your plan's specialty-drug copay, coinsurance tier, and whether it applies toward your deductible. 3. Tell your allergist's office if cost is a concern — most specialty practices have staff experienced in submitting PAs and connecting patients with assistance programs.

Gale can help you identify an allergist in your area and prepare questions to bring to your first visit.

Common questions

Is Xolair covered under Medicare for chronic hives?

Yes. When administered in a physician's office, Xolair is billed under Medicare Part B as a physician-administered drug. You are typically responsible for 20% of the Medicare-approved amount after the Part B deductible, which can still be substantial. A Medicare Supplement (Medigap) plan may cover that 20%. Manufacturer copay cards are not available for Medicare patients, but the Genentech patient assistance program may apply.

How long does prior authorization for Xolair usually take?

Most commercial insurers respond within 3–14 business days for a standard review. Urgent requests can be processed faster. Incomplete documentation — particularly missing records of prior antihistamine trials — is the most common cause of delays.

Can I get Xolair at a pharmacy instead of a clinic?

Some specialty pharmacies dispense Xolair for home administration, though most clinicians prefer in-office dosing to allow monitoring for the rare but serious risk of anaphylaxis. Your insurer's coverage (Part B vs. Part D) may also depend on where it is administered.

What specialist prescribes Xolair for chronic hives?

An allergist-immunologist most commonly prescribes Xolair for chronic urticaria. Some dermatologists also prescribe it. You will need a specialist referral — a primary care clinician can start the referral if you do not already have one.

Talk to a clinician

Gale can match you with a licensed clinician for a visit.

Find care →

When to seek care sooner

  • —Hives with throat tightening, difficulty breathing, or swelling of the lips or tongue — this is a possible anaphylactic reaction; call 911 immediately
  • —Any reaction within 30 minutes of a Xolair injection — remain in the clinic for observation as directed
  • —Sudden worsening of hives or new symptoms while on Xolair

This article provides general cost and process information, not personalized medical or financial advice. Drug prices change frequently. Consult your allergist and insurance plan for current figures that apply to your situation.

References

  1. 1.U.S. Food and Drug Administration / Genentech (2024). XOLAIR (omalizumab) Prescribing Information. FDA / Genentech. link ✓FDA-approved indication for chronic spontaneous urticaria in patients 12 and older who remain symptomatic despite H1-antihistamine treatment; approved dose 150 or 300 mg SC every 4 weeks; 30-minute observation requirement; anaphylaxis risk at any dose.
  2. 2.Maurer M, Rosén K, Hsieh HJ, Saini S, Grattan C, Gimenéz-Arnau A, et al. (2013). Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. New England Journal of Medicine. doi:10.1056/NEJMoa1215372 ✓ASTERIA II Phase III trial: 300 mg omalizumab produced significantly greater reduction in weekly itch-severity score vs. placebo at week 12 (mean change -9.8 vs. -5.1, P<0.001) in patients with chronic idiopathic/spontaneous urticaria refractory to H1 antihistamines.
  3. 3.Lieberman P, Mink L, et al. (Joint Task Force on Practice Parameters, AAAAI/ACAAI) (2023). Anaphylaxis: A 2023 practice parameter update. Annals of Allergy, Asthma and Immunology. doi:10.1016/j.anai.2023.09.015 ✓Anaphylaxis risk with biologic injections including omalizumab; 30-minute observation period standard after injectable biologics; epinephrine as first-line treatment if anaphylaxis occurs after any dose.

3 sources, numbered by first appearance. General health information, not medical advice — synthetic demonstration content.